← All trials
NCT00991341
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jan 1, 2010
- Primary completion
- Mar 1, 2014
- Completion date
- Mar 1, 2014
- First posted
- —
- Last posted
- —
- Enrollment
- 1481
- Arms / groups
- 2 / —
- Source
- AACT · pre-existing
Sponsors
- New England Research InstitutesLead sponsor
- National Heart, Lung, and Blood Institute (NHLBI)Collaborator
- New England Research InstitutesOverall official - principal investigator
- Duke UniversityOverall official - principal investigator
- Emory UniversityOverall official - principal investigator
- Johns Hopkins UniversityOverall official - principal investigator
- University of IowaOverall official - principal investigator
- University of MarylandOverall official - principal investigator
- Vanderbilt UniversityOverall official - principal investigator
- University of OklahomaOverall official - principal investigator
- Mayo ClinicOverall official - principal investigator
- Texas Heart InstituteOverall official - principal investigator
- University of FloridaOverall official - principal investigator
- University of MassachusettsOverall official - principal investigator
- Froedtert Memorial Lutheran HospitalOverall official - principal investigator
- Aspirus Medical CenterOverall official - principal investigator
- University of MinnesotaOverall official - principal investigator
- Columbia UniversityOverall official - principal investigator
- Cornell UniversityOverall official - principal investigator
- University of North Carolina at Chapel HillOverall official - principal investigator
- University of PittsburghOverall official - principal investigator
- University of WashingtonOverall official - principal investigator
- Sanford HealthOverall official - principal investigator
- St. Elizabeth's Medical Center of BostonOverall official - principal investigator
- Newark Beth Israel Medical CenterOverall official - principal investigator
- Harvard UniversityOverall official - principal investigator
- Rutgers UniversityOverall official - principal investigator
- The University of Texas, DallasOverall official - principal investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.